Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
157 hedge funds and large institutions have $1.42B invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 16 closing their positions.
460% more call options, than puts
Call options by funds: $5.61M | Put options by funds: $1M
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
1% more funds holding
Funds holding: 155 → 157 (+2)
5% less capital invested
Capital invested by funds: $1.49B → $1.42B (-$67.2M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$31.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$25.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.1M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.5M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$25.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.51M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.83M |
| 5 |
Millennium Management
New York
|
-$4.58M |
KDNY Hedge Fund Activity: Q1 2023 in Review
157 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2023, worth a combined $1.42B — down 4.5% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KDNY positions and 16 closed out — a net gain of 4 holders — while 57 added to existing stakes and 49 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $31.3M. The largest seller was Baker Bros. Advisors, cutting an estimated $25.7M.
- 157 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2023, up from 155 in Q4 2022.
- Funds reported $1.42B of Chinook Therapeutics, Inc. Common Stock stock for Q1 2023, down 4.5% quarter-over-quarter.
- 20 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2023 and 16 closed out, a net change of +4 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2023 was Franklin Resources, an estimated $31.3M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2023 was Baker Bros. Advisors, an estimated $25.7M sold.
Based on aggregated 13F filings for Q1 2023.